AxoGen and Blueprint Medicines Help Opaleye Return 91% Over the Last Year
James A. Silverman founded Opaleye Management back in 1996 and it was formerly known as Risk/Reward Capital.
Opaleye Management, formerly known as Risk/Reward Capital Management Corporation, is a hedge fund management firm based in Massachusetts. Founded by James Silverman in February 1996, the firm focuses on investing in small and mid-sized biotechnology and specialty pharmaceutical companies both in the United States and internationally. The name change to Opaleye Management occurred in 2014, reflecting the firm's evolving strategy and vision.
James Aaron Silverman is the founder and currently serves as President and Chief Compliance Officer at Opaleye Management, Inc., which he established in 1996. Prior to founding Opaleye, he was a Director at Cheech & Chong's Cannabis Co. Mr. Silverman earned his undergraduate degree from George Washington University.
Opaleye Management is a hedge fund managing $432,480,569 in discretionary assets for 2 clients, as of their Form ADV filing on March 2024. Their Q1 2024 13F filing reported $458,857,064 in managed securities, with the top 10 holdings comprising 57.01% of the portfolio. The firm's largest position is in Ocular Therapeutix Inc., holding 6,653,138 shares.
